M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Pirtobrutinib
Drug: Venetoclax

First Posted Date: 2022-04-08

Last Posted Date: 2024-10-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT05317936

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

POWER UP: Participating Online While Exercising to Recover Using Play

Not Applicable

Suspended

Conditions: Exercise
Central Nervous System Tumors
Tumors

Interventions: Other: Focus Groups
Other: Pilot randomized controlled trial

First Posted Date: 2022-04-04

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT05308407

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Barriers and Facilitators in Access to OT/PT in Pediatric Cancer Survivors

Active, not recruiting

Conditions: Pediatric Cancer

Interventions: Other: Patient population

First Posted Date: 2022-03-31

Last Posted Date: 2024-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05305950

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Phase 2

Withdrawn

Conditions: Stem Cell Transplantation

Interventions: Drug: Fludarabine
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Cyclophosphamide (Cy)
Drug: Bortezomib
Drug: Rituximab
Drug: Mycophenolate mofetil (MMF)
Drug: Busulfan
Drug: Rabbit ATG
Drug: Tacrolimus (or cyclosporine)

First Posted Date: 2022-03-24

Last Posted Date: 2023-09-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05293509

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Development of an Application-Based Digital Navigator for Perioperative Breast Surgery Patients

Recruiting

Conditions: Breast

Interventions: Other: JEEVA (new digital health navigator app)

First Posted Date: 2022-03-22

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT05290402

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Not Applicable

Recruiting

Conditions: Fallopian Tube Cancer
Ovarian Cancer

Interventions: Other: Risk-Reducing Salpingo-Oophorectomy-RRSO
Other: RIsk-Reducing Salpingectomy (RRS)
Other: Risk-Reducing Oophorectomy-RRO

First Posted Date: 2022-03-18

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05287451

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Harvard Cancer Center, Boston, Massachusetts, United States

and more 1 locations

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Phase 2

Recruiting

Conditions: AML
MDS

Interventions: Drug: Vibecotamab
Drug: Dexamethasone
Drug: Acetaminophen
Drug: Diphenhydramine

First Posted Date: 2022-03-18

Last Posted Date: 2024-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT05285813

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1

Active, not recruiting

Conditions: Tumor
Adenocarcinoma

Interventions: Drug: Pembrolizumab
Drug: lenvatinib

First Posted Date: 2022-03-10

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT05273554

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Mini-hyper CVD
Drug: Ponatinib
Drug: Venetoclax

First Posted Date: 2022-03-07

Last Posted Date: 2024-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT05268003

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase 1

Terminated

Conditions: Metastatic Breast Cancer
Breast Cancer

Interventions: Drug: Neratinib
Drug: Capmatinib

First Posted Date: 2022-02-17

Last Posted Date: 2024-11-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05243641

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy